Current:Home > FinanceThe FDA is weighing whether to approve MDMA for PTSD. Here's what that could look like for patients.-LoTradeCoin
The FDA is weighing whether to approve MDMA for PTSD. Here's what that could look like for patients.
View Date:2024-12-24 00:35:24
Ahead of a key meeting Tuesday to weigh the potential approval of midomafetamine, or MDMA, for patients with post-traumatic stress disorder, the Food and Drug Administration is proposing a new set of restrictions on how eligible patients would be able to get the drug.
Details of the FDA's proposal were published Friday in a set of documents released by the agency ahead of an advisory committee meeting next week.
After the panel votes, drugmaker Lykos Therapeutics says the FDA is expected to make a decision by Aug. 11 on whether to approve its approach for patients with PTSD: a four-month course of MDMA combined with psychotherapy.
Among the FDA's questions for the committee is whether the benefits of MDMA, combined with the FDA's proposed restrictions on prescriptions for the hallucinogenic drug, will be enough to outweigh its risks.
"Patient impairment is an expected effect from midomafetamine administration and there must be safeguards to mitigate serious harm from patient impairment, similar to the risk mitigation in the clinical trials, to support patient safety," the FDA's reviewers said in a briefing document ahead of the meeting.
Under the proposal, administering MDMA would be restricted to healthcare facilities that agree to ensure at least two providers are onsite to monitor patients while taking the drug.
Patients will need to be monitored for at least eight hours, until they are psychologically stable enough to be discharged to an adult after the session. During the trials, many ended up staying overnight at study sites, being monitored by therapists.
Providers will also need to prepare for some physical risks. In the trials, one participant was hospitalized after MDMA was suspected to have exacerbated a pre-existing heart problem.
Patients will also need to be enrolled in a registry tracking side effects and issues that come up from the sessions, as well as how they are faring following completion of the treatment.
"We are also concerned about worsening of psychological disorders that cause disability or that may lead to hospitalization or death, and suicidal behaviors and ideation," the FDA said.
The drugmaker has also been in talks with the FDA over other steps to curb risks of the drug, like providing the product in only single dose packages aimed at limiting the risk of "nonmedical use," Lykos said in their briefing document.
The FDA often turns to its authority to apply additional restrictions on prescription drugs, dubbed Risk Evaluation and Mitigation Strategies or REMS, to curb the pitfalls of drugs that it thinks would otherwise be too dangerous to approve.
Nasal sprays of hallucinogen esketamine to treat depression, branded as Spravato, were also approved in 2019 under these kinds of REMS restrictions.
Additional restrictions could be imposed by a different agency – the Drug Enforcement Administration – which will be responsible for "rescheduling" the drug.
The DEA currently deems MDMA or "ecstasy" to be a Schedule I drug, alongside other substances like heroin which the DEA says have "no currently accepted medical use and a high potential for abuse."
Alexander TinAlexander Tin is a digital reporter for CBS News based in the Washington, D.C. bureau. He covers the Biden administration's public health agencies, including the federal response to infectious disease outbreaks like COVID-19.
TwitterveryGood! (66484)
Related
- 'We suffered great damage': Fierce California wildfire burns homes, businesses
- Latin group RBD returns after 15-year hiatus with a message: Pop is not dead
- Luxembourg’s coalition under Bettel collapses due to Green losses in tight elections
- Gates Foundation funding $40 million effort to help develop mRNA vaccines in Africa in coming years
- Spirit Airlines cancels release of Q3 financial results as debt restructuring talks heat up
- Texas Rangers slam Baltimore Orioles, take commanding 2-0 ALDS lead
- Simone Biles wins something more important than medals at world championships
- Horoscopes Today, October 7, 2023
- Olivia Munn Says She “Barely Knew” John Mulaney When She Got Pregnant With Their Son
- Can cooking and gardening at school inspire better nutrition? Ask these kids
Ranking
- NFL Week 10 injury report: Live updates on active, inactive players for Sunday's games
- AJ Allmedinger wins at Charlotte; Kyle Busch, Bubba Wallace eliminated from NASCAR playoffs
- Azerbaijan’s leader says his country is ready to hold peace treaty talks with Armenia
- Investigators: Pilot error was cause of 2021 plane crash that killed 4 in Michigan
- TikToker Campbell “Pookie” Puckett Gives Birth, Welcomes First Baby With Jett Puckett
- The auto workers’ strike enters its 4th week. The union president urges members to keep up the fight
- An autopsy rules that an Atlanta church deacon’s death during his arrest was a homicide
- Evacuations ordered as remnants of Typhoon Koinu hit southern China
Recommendation
-
Who's hosting 'SNL' tonight? Musical guest, start time, where to watch Nov. 9 episode
-
California Gov. Gavin Newsom vetoes bill to make free condoms available for high school students
-
Schools’ pandemic spending boosted tech companies. Did it help US students?
-
Stock market today: Asian markets are mixed, oil prices jump and Israel moves to prop up the shekel
-
Atmospheric river to bring heavy snow, rain to Northwest this week
-
See states with the most student debt as Biden Administration moves in on new deal
-
Impeachments and forced removals from office emerge as partisan weapons in the states
-
Food Network Star Michael Chiarello Dead at 61